CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.

Phase 3

Novaliq GmbH

Ophthalmic Solutions